A Trial to Evaluate BMS-298585 as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control
NCT ID: NCT00246987
Last Updated: 2012-04-27
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
341 participants
INTERVENTIONAL
2003-06-30
2004-04-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study to Evaluate Combining Metformin With Muraglitazar or Pioglitazone in Type 2 Diabetics
NCT00240370
Mechanism of Action and Efficacy of Muraglitazar in Type 2 Diabetes
NCT00094991
Dose Ranging Study With LT, Monotherapy, PPAR
NCT00240383
PPAR-COMBO With Sulfonylurea
NCT00162175
Safety Study of BMS-903452 in Healthy Subjects (Panel 1-7) & Relative Bioavailability of the Crystalline and Amorphous Forms of BMS-903452 [Panels 4, 6, 11 & 12(Part A)], and Subjects With Type 2 Diabetes Mellitus (Part B)
NCT01240980
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Muraglitazar
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Drug Naive
* HbA1c \>= 7.0% and \<= 10.0%
* Body Mass Index \<= 41 kg/m2
* Serum TG \<= 600 mg/dL
Exclusion Criteria
* History of bladder cancer
* History of Myocardial Infarction (MI), coronary angioplasty or bypass grafts, valvular disease or repair, unstable angina pectoris, Transient Ischemic Attach (TIA), or Cerebrovascular Accident (CVA) within 6 months, congestive heart failure (NYHA Class II and IV), uncontrolled hypertension, history of renal disease, peripheral vascular disease (PVD), pulmonary disease, gastrointestinal disease, active liver disease or endocrine disease.
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Bristol-Myers Squibb
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Local Institution
Anniston, Alabama, United States
Local Institution
Birmingham, Alabama, United States
Local Institution
Haleyville, Alabama, United States
Local Institution
Hoover, Alabama, United States
Local Institution
Fayetteville, Arizona, United States
Local Institution
Hot Springs, Arizona, United States
Local Institution
Mesa, Arizona, United States
Local Institution
Phoenix, Arizona, United States
Local Institution
Tucson, Arizona, United States
Local Institution
Tulsa, Arizona, United States
Local Institution
Concord, California, United States
Local Institution
Fountain Valley, California, United States
Local Institution
Long Beach, California, United States
Local Institution
Los Gatos, California, United States
Local Institution
Raleigh, California, United States
Local Institution
Roseville, California, United States
Local Institution
San Diego, California, United States
Local Institution
Spring Valley, California, United States
Local Institution
Tustin, California, United States
Local Institution
Colorado Springs, Colorado, United States
Local Institution
Golden, Colorado, United States
Local Institution
Littleton, Colorado, United States
Local Institution
New Britain, Connecticut, United States
Local Institution
Altamonte Springs, Florida, United States
Local Institution
Brandon, Florida, United States
Local Institution
Chipley, Florida, United States
Local Institution
Coral Gables, Florida, United States
Local Institution
Kissimmee, Florida, United States
Local Institution
Longwood, Florida, United States
Local Institution
Melbourne, Florida, United States
Local Institution
New Port Richie, Florida, United States
Local Institution
Ocala, Florida, United States
Local Institution
Pinellas Park, Florida, United States
Local Institution
Chicago, Illinois, United States
Local Institution
Overland Park, Kansas, United States
Local Institution
Shawnee Mission, Kansas, United States
Local Institution
Lexington, Kentucky, United States
Local Institution
Madisonville, Kentucky, United States
Local Institution
Shreveport, Louisiana, United States
Local Institution
Gulfport, Mississippi, United States
Local Institution
Saint Peters, Mississippi, United States
Local Institution
Chesterfield, Missouri, United States
Local Institution
Kansas City, Missouri, United States
Local Institution
Springfield, Missouri, United States
Local Institution
Elizabeth, New Jersey, United States
Local Institution
Toms River, New Jersey, United States
Local Institution
Endwell, New York, United States
Local Institution
West Seneca, New York, United States
Local Institution
Charlotte, North Carolina, United States
Local Institution
High Point, North Carolina, United States
Local Institution
Morehead City, North Carolina, United States
Local Institution
Salisbury, North Carolina, United States
Local Institution
Winston-Salem, North Carolina, United States
Local Institution
Franklin, Ohio, United States
Local Institution
Newark, Ohio, United States
Local Institution
Zanesville, Ohio, United States
Local Institution
Eugene, Oregon, United States
Local Institution
Portland, Oregon, United States
Local Institution
Philadelphia, Pennsylvania, United States
Local Institution
Reading, Pennsylvania, United States
Local Institution
Warminster, Pennsylvania, United States
Local Institution
East Providence, Rhode Island, United States
Local Institution
Johnston, Rhode Island, United States
Local Institution
Providence, Rhode Island, United States
Local Institution
Anderson, South Carolina, United States
Local Institution
Greer, South Carolina, United States
Local Institution
Mt. Pleasant, South Carolina, United States
Local Institution
Knoxville, Tennessee, United States
Local Institution
Memphis, Tennessee, United States
Local Institution
Fort Worth, Texas, United States
Local Institution
Lubbock, Texas, United States
Local Institution
San Angelo, Texas, United States
Local Institution
San Antonio, Texas, United States
Local Institution
Salt Lake City, Utah, United States
Local Institution
Richmond, Virginia, United States
Local Institution
Virginia Beach, Virginia, United States
Local Institution
Edmonds, Washington, United States
Local Institution
Federal Way, Washington, United States
Local Institution
Olympia, Washington, United States
Local Institution
Spokane, Washington, United States
Local Institution
Vancouver, Washington, United States
Local Institution
Milwaukee, Wisconsin, United States
Local Institution
Canberra, New South Wales, Australia
Local Institution
Sydney, New South Wales, Australia
Local Institution
Wollongong, New South Wales, Australia
Local Institution
Kippa-Ring, Queensland, Australia
Local Institution
Meadowbrook, Queensland, Australia
Local Institution
Adelaide, South Australia, Australia
Local Institution
Woodville, South Australia, Australia
Local Institution
Launceston, Tasmania, Australia
Tasmania
Melbourne, Victoria, Australia
Local Institution
Calgary, Alberta, Canada
Local Institution
Edmonton, Alberta, Canada
Local Institution
Coquitlam, British Columbia, Canada
Local Institution
Winnipeg, Manitoba, Canada
Local Institution
Manuels, Newfoundland and Labrador, Canada
Local Institution
St. John's, Newfoundland and Labrador, Canada
Local Institution
Halifax, Nova Scotia, Canada
Local Institution
Markham, Ontario, Canada
Local Institution
Oakville, Ontario, Canada
Local Institution
Ottawa, Ontario, Canada
Local Institution
Thornhill, Ontario, Canada
Local Institution
Thunder Bay, Ontario, Canada
Local Institution
Toronto, Ontario, Canada
Local Institution
Charlottetown, Prince Edward Island, Canada
Local Institution
Chicoutimi, Quebec, Canada
Local Institution
Drummondville, Quebec, Canada
Local Institution
Granby, Quebec, Canada
Local Institution
Laval, Quebec, Canada
Local Institution
Longueuil, Quebec, Canada
Local Institution
Montreal, Quebec, Canada
Local Institution
Pointe-Claire, Quebec, Canada
Local Institution
Saint-Lambert, Quebec, Canada
Local Institution
Ste-Foy, Quebec, Canada
Local Institution
Regina, Saskatchewan, Canada
Local Institution
Saskatoon, Saskatchewan, Canada
Local Institution
Aguascalientes, Aguascalientes, Mexico
Local Institution
Durango, Durango, Mexico
Local Institution
Mexico City, Mexico City, Mexico
Local Institution
Cuernavaca, Morelos, Mexico
Local Institution
Krakow, , Poland
Local Institution
Lodz, , Poland
Local Institution
Mroków, , Poland
Local Institution
Warsaw, , Poland
Local Institution
Zabrze, , Poland
Local Institution
Añasco, , Puerto Rico
Local Institution
Ponce, , Puerto Rico
Local Institution
Rio Pieoras, , Puerto Rico
Local Institution
Changhua, , Taiwan
Local Institution
Taichung, , Taiwan
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CV168-018
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.